Insider Trading activities at Lb Pharmaceuticals Inc (LBRX)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Lb Pharmaceuticals Inc (LBRX) since 2025 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Lb Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1691082.

Total stock buying since 2025: $74,999,985.
Total stock sales since 2025: $0.
Total stock option exercises since 2025: $0.


4 insiders reported insider trading activities at Lb Pharmaceuticals Inc (LBRX):
Insider trading activities of Kroin David
Insider trading activities of Pontifax Management 4 G.p. (2015) Ltd.
Insider trading activities of Vida Ventures Management Co. Llc
Insider trading activities of Nussbaum Ran

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Lb Pharmaceuticals Inc (LBRX).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2025 4,999,999 $74,999,985 0 $0 0 $0

Table 2. Monthly summary of insider trading at Lb Pharmaceuticals Inc (LBRX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2025-09 4,999,999 $74,999,985 0 $0 0 $0

Table 3. Detailed insider trading at Lb Pharmaceuticals Inc (LBRX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2025-09-12 Vida Ventures Management Co. Llc Buy 333,333 15.00 4,999,995
2025-09-12 Pontifax Management 4 G.p. (2015) Ltd. Buy 1,000,000 15.00 15,000,000
2025-09-12 Nussbaum Ran Buy 1,000,000 15.00 15,000,000
2025-09-12 Kroin David Buy 2,666,666 15.00 39,999,990

Insider trading activities including stock purchases, stock sales, and option exercises of LBRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Lb Pharmaceuticals Inc (symbol LBRX, CIK number 1691082) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.